Pfiz­er wins first US ap­proval for pen­tava­lent meningo­coc­cal vac­cine 

Pfiz­er on Fri­day won ap­proval for its next mass-mar­ket vac­cine, a pen­tava­lent meningo­coc­cal vac­cine cov­er­ing the most com­mon serogroups in­fect­ing chil­dren and young adults ages …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER